52,000-square-foot corporate headquarters in San Diego with R&D and GMP manufacturing center Builds on current capability at Artiva’s partner, GC Cell’s facility in Republic of Korea Custom-built GMP manufacturing center further enables Artiva’s leadership position in scaled, off-the-shelf NK and CAR-NK therapeutic manufacturing for treatment of solid and hematological cancers SAN DIEGO, June 13, 2022…
SAN DIEGO, June 6, 2022 – Artiva Biotherapeutics, Inc., an oncology company whose mission is to deliver highly effective, off-the-shelf allogeneic natural killer (NK) cell therapies that are safe and accessible to cancer patients, today announced the appointment of Thorsten Graef, M.D., Ph.D., as Chief Medical Officer. As a highly respected drug development leader, Dr….
SAN DIEGO, May 5, 2022 — Artiva Biotherapeutics, Inc., an oncology company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies that are safe and accessible to cancer patients, today announced the appointment of Edith A. Perez, M.D., as a member of the Company’s Board of Directors. In addition, Dr….
Artiva to provide clinical-grade NK cells from its AlloNKTM platform for assessment in combination with tri-specific NK-cell engagers SAN DIEGO, April 11, 2022 — Artiva Biotherapeutics, Inc., an oncology company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell therapies to treat cancer, announced today that it has entered into an…
SAN DIEGO, March 3, 2022 — Artiva Biotherapeutics, Inc., an oncology company with a mission to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies that are safe and accessible to cancer patients, today announced the appointment of Laura Bessen, M.D., as an independent member of the Company’s board of directors. Dr. Bessen brings…
SAN DIEGO, January 4, 2022 — Artiva Biotherapeutics, Inc., an oncology company focused on developing and commercializing primary allogeneic natural killer (NK) cell therapies to treat cancer, today announced the appointment of Christopher Horan as Chief Technical Operations Officer. As a leader in therapeutic technical operations, Mr. Horan brings more than 30 years of experience managing…
Company to present preclinical data for AB-201, an anti-HER2-specific CAR-NK cell therapy candidate developed with Artiva’s AlloNKTM Platform Data highlight scaled production and anti-tumor activity in support of clinical development for the treatment of HER2+ solid tumors SAN DIEGO, October 21, 2021 – Artiva Biotherapeutics, Inc., (“Artiva”) an oncology company focused on developing and commercializing…
As one of the first biotechs to join Pledge 1%, Artiva is forging a way to integrate philanthropy into a biotech company’s mission and culture SAN DIEGO, September 30, 2021 – Artiva Biotherapeutics, Inc., (“Artiva”) announced today that it has joined Pledge 1%, a global movement that supports the integration of philanthropy into corporate culture…
52,000-square-foot corporate headquarters in San Diego with R&D and GMP manufacturing center to open in 2022 Builds on current capability at Artiva’s partner, GC LabCell’s facility in Republic of Korea Custom-built GMP manufacturing center further expands Artiva’s leadership position in scaled, off-the-shelf NK and CAR-NK therapeutic manufacturing for treatment of solid and hematological cancers SAN…